Fujifilm Irvine Scientific has plans in the works to open a third manufacturing facility located in Tilburg, Netherlands. The company that specialises in cell culture media currently also has sites in the US and Japan.
The facility will occupy a 250,000 sqft building within Fujifilm Manufacturing Europe, one of the largest Fujifilm production centres outside of Japan.
The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids, thereby adding additional production capacity of 320,000 kg/year for dry powder, and 470,000 L/year for liquids.
Water for Injection (WFI) will also be manufactured on the premises.
The company’s current capacity is >1,000,000 kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide
“The biopharmaceutical market is growing at a high rate, and cell therapies are moving into clinical trials and commercialisation at fast pace. The company’s current capacity is >1,000,000 kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide, as well as meet our European customer demand for regional support,” said Yutaka Yamaguchi, Fujifilm CEO.
Yamaguchi continued to say that this third, world-class cGMP manufacturing facility will serve as a European hub for rapid, reliable supply of products.
Work on the new manufacturing site has begun and it is expected to be commissioned in the second half of 2021.
